{"transactions":[{"id":743406,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:35:21.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":19475,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option vest upon the earlier of (i) June 9, 2027 or (ii) the date of the next Annual Meeting of Stockholders of Bicara Therapeutics Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":19475,"derivative":{"exercise_price":20.56,"expiration_date":"2036-06-09","underlying":"Common Stock","underlying_shares":19475},"source":{"system":"sec-edgar","filing":"0001628280-26-042255","document":"wk-form4_1781123718.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2023658/000162828026042255/wk-form4_1781123718.xml","form_type":"4"}},{"id":1116609,"issuer":{"id":4673,"kind":"organization","name":"Bicara Therapeutics Inc.","symbol":"BCAX"},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-10T20:26:32.000Z","date":"2025-06-09","kind":"grant","planned":false,"acquired":true,"shares":23746,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was awarded to the reporting person pursuant to the Issuer's 2024 Stock Option and Incentive Plan. The shares underlying this option shall vest upon the earlier of (i) June 9, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":23746,"derivative":{"exercise_price":11.48,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":23746},"source":{"system":"sec-edgar","filing":"0002023658-25-000073","document":"wk-form4_1749587186.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2023658/000202365825000073/wk-form4_1749587186.xml","form_type":"4"}},{"id":2222274,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-06-24T20:31:03.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments beginning on July 13, 2022."}],"balance_after":100000,"derivative":{"exercise_price":0.82,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-22-023978","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000089924322023978/doc4.xml","form_type":"4"}},{"id":2222273,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-24T20:31:03.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":44167,"source":{"system":"sec-edgar","filing":"0000899243-22-023978","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000089924322023978/doc4.xml","form_type":"4"}},{"id":2658714,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-06-22T20:44:19.000Z","date":"2021-06-18","kind":"exercise","acquired":false,"shares":46608,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 21, 2017. The shares underlying this option vest as to 25% of the underlying shares on February 21, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":992,"derivative":{"exercise_price":50.4,"expiration_date":"2027-02-20","underlying":"Common stock","underlying_shares":46608},"source":{"system":"sec-edgar","filing":"0001439222-21-000059","document":"wf-form4_162439463312605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000059/wf-form4_162439463312605.xml","form_type":"4"}},{"id":2658713,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-06-22T20:44:19.000Z","date":"2021-06-18","kind":"exercise","acquired":false,"shares":1885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":1885},"source":{"system":"sec-edgar","filing":"0001439222-21-000059","document":"wf-form4_162439463312605.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000059/wf-form4_162439463312605.xml","form_type":"4"}},{"id":2658712,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-22T20:44:19.000Z","date":"2021-06-18","kind":"sale","acquired":false,"shares":48493,"price":60.1087,"value":2914851.1891,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.31. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":15487,"source":{"system":"sec-edgar","filing":"0001439222-21-000059","document":"wf-form4_162439463312605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000059/wf-form4_162439463312605.xml","form_type":"4"}},{"id":2658711,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-22T20:44:19.000Z","date":"2021-06-18","kind":"exercise","acquired":true,"shares":46608,"price":50.4,"value":2349043.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":63980,"source":{"system":"sec-edgar","filing":"0001439222-21-000059","document":"wf-form4_162439463312605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000059/wf-form4_162439463312605.xml","form_type":"4"}},{"id":2658710,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-22T20:44:19.000Z","date":"2021-06-18","kind":"exercise","acquired":true,"shares":1885,"price":39.76,"value":74947.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17372,"source":{"system":"sec-edgar","filing":"0001439222-21-000059","document":"wf-form4_162439463312605.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000059/wf-form4_162439463312605.xml","form_type":"4"}},{"id":2660797,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-06-21T20:18:29.000Z","date":"2021-06-17","kind":"exercise","acquired":false,"shares":2502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":1885,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":2502},"source":{"system":"sec-edgar","filing":"0001439222-21-000058","document":"wf-form4_162430668613104.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000058/wf-form4_162430668613104.xml","form_type":"4"}},{"id":2660796,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-21T20:18:29.000Z","date":"2021-06-17","kind":"sale","acquired":false,"shares":2502,"price":60.0198,"value":150169.5396,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.09. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":15487,"source":{"system":"sec-edgar","filing":"0001439222-21-000058","document":"wf-form4_162430668613104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000058/wf-form4_162430668613104.xml","form_type":"4"}},{"id":2660795,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-21T20:18:29.000Z","date":"2021-06-17","kind":"exercise","acquired":true,"shares":2502,"price":39.76,"value":99479.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17989,"source":{"system":"sec-edgar","filing":"0001439222-21-000058","document":"wf-form4_162430668613104.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000058/wf-form4_162430668613104.xml","form_type":"4"}},{"id":2671771,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-06-11T21:00:31.000Z","date":"2021-06-10","kind":"exercise","acquired":false,"shares":20853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":4387,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":20853},"source":{"system":"sec-edgar","filing":"0001439222-21-000057","document":"wf-form4_162344520927067.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000057/wf-form4_162344520927067.xml","form_type":"4"}},{"id":2671770,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-06-11T21:00:31.000Z","date":"2021-06-09","kind":"exercise","acquired":false,"shares":7149,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":25240,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":7149},"source":{"system":"sec-edgar","filing":"0001439222-21-000057","document":"wf-form4_162344520927067.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000057/wf-form4_162344520927067.xml","form_type":"4"}},{"id":2671769,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-11T21:00:31.000Z","date":"2021-06-10","kind":"sale","acquired":false,"shares":20853,"price":60.0603,"value":1252437.4359,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.29. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":15487,"source":{"system":"sec-edgar","filing":"0001439222-21-000057","document":"wf-form4_162344520927067.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000057/wf-form4_162344520927067.xml","form_type":"4"}},{"id":2671768,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-11T21:00:31.000Z","date":"2021-06-10","kind":"exercise","acquired":true,"shares":20853,"price":39.76,"value":829115.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":36340,"source":{"system":"sec-edgar","filing":"0001439222-21-000057","document":"wf-form4_162344520927067.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000057/wf-form4_162344520927067.xml","form_type":"4"}},{"id":2671767,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-11T21:00:31.000Z","date":"2021-06-09","kind":"sale","acquired":false,"shares":7149,"price":60.1646,"value":430116.7254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.60. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":15487,"source":{"system":"sec-edgar","filing":"0001439222-21-000057","document":"wf-form4_162344520927067.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000057/wf-form4_162344520927067.xml","form_type":"4"}},{"id":2671766,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-11T21:00:31.000Z","date":"2021-06-09","kind":"exercise","acquired":true,"shares":7149,"price":39.76,"value":284244.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":22636,"source":{"system":"sec-edgar","filing":"0001439222-21-000057","document":"wf-form4_162344520927067.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000057/wf-form4_162344520927067.xml","form_type":"4"}},{"id":2675504,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-06-09T20:06:25.000Z","date":"2021-06-08","kind":"exercise","acquired":false,"shares":6675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":32389,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":6675},"source":{"system":"sec-edgar","filing":"0001439222-21-000056","document":"wf-form4_162326917068520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000056/wf-form4_162326917068520.xml","form_type":"4"}},{"id":2675503,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-06-09T20:06:25.000Z","date":"2021-06-07","kind":"exercise","acquired":false,"shares":4268,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":39064,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":4268},"source":{"system":"sec-edgar","filing":"0001439222-21-000056","document":"wf-form4_162326917068520.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000056/wf-form4_162326917068520.xml","form_type":"4"}},{"id":2675502,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-09T20:06:25.000Z","date":"2021-06-08","kind":"sale","acquired":false,"shares":6675,"price":60.0657,"value":400938.5475,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.13. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":15487,"source":{"system":"sec-edgar","filing":"0001439222-21-000056","document":"wf-form4_162326917068520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000056/wf-form4_162326917068520.xml","form_type":"4"}},{"id":2675501,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-09T20:06:25.000Z","date":"2021-06-08","kind":"exercise","acquired":true,"shares":6675,"price":39.76,"value":265398.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":22162,"source":{"system":"sec-edgar","filing":"0001439222-21-000056","document":"wf-form4_162326917068520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000056/wf-form4_162326917068520.xml","form_type":"4"}},{"id":2675500,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-09T20:06:25.000Z","date":"2021-06-07","kind":"sale","acquired":false,"shares":4268,"price":60.0357,"value":256232.3676,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.00 to $60.10. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":15487,"source":{"system":"sec-edgar","filing":"0001439222-21-000056","document":"wf-form4_162326917068520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000056/wf-form4_162326917068520.xml","form_type":"4"}},{"id":2675499,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-06-09T20:06:25.000Z","date":"2021-06-07","kind":"exercise","acquired":true,"shares":4268,"price":39.76,"value":169695.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":19755,"source":{"system":"sec-edgar","filing":"0001439222-21-000056","document":"wf-form4_162326917068520.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000056/wf-form4_162326917068520.xml","form_type":"4"}},{"id":2725337,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-06T23:20:19.000Z","date":"2021-03-04","kind":"grant","acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021."}],"balance_after":31250,"derivative":{"exercise_price":4.31,"expiration_date":"2031-03-03","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001209191-21-030737","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919121030737/doc4.xml","form_type":"4"}},{"id":2725336,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T23:20:19.000Z","date":"2021-03-04","kind":"grant","acquired":true,"shares":4167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares will vest on 5/19/2021."}],"balance_after":4167,"source":{"system":"sec-edgar","filing":"0001209191-21-030737","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919121030737/doc4.xml","form_type":"4"}},{"id":2742990,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-04-21T21:11:43.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":1888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":43332,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":1888},"source":{"system":"sec-edgar","filing":"0001439222-21-000036","document":"wf-form4_161903949035322.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000036/wf-form4_161903949035322.xml","form_type":"4"}},{"id":2742989,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-04-21T21:11:43.000Z","date":"2021-04-20","kind":"exercise","acquired":false,"shares":12513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":12513},"source":{"system":"sec-edgar","filing":"0001439222-21-000036","document":"wf-form4_161903949035322.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000036/wf-form4_161903949035322.xml","form_type":"4"}},{"id":2742988,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-04-21T21:11:43.000Z","date":"2021-04-19","kind":"exercise","acquired":false,"shares":3210,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":12513,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":3210},"source":{"system":"sec-edgar","filing":"0001439222-21-000036","document":"wf-form4_161903949035322.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000036/wf-form4_161903949035322.xml","form_type":"4"}},{"id":2742987,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-04-21T21:11:43.000Z","date":"2021-04-20","kind":"sale","acquired":false,"shares":14401,"price":55.106,"value":793581.506,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $55.00 to $55.34. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":15487,"source":{"system":"sec-edgar","filing":"0001439222-21-000036","document":"wf-form4_161903949035322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000036/wf-form4_161903949035322.xml","form_type":"4"}},{"id":2742986,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-04-21T21:11:43.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":1888,"price":39.76,"value":75066.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":29888,"source":{"system":"sec-edgar","filing":"0001439222-21-000036","document":"wf-form4_161903949035322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000036/wf-form4_161903949035322.xml","form_type":"4"}},{"id":2742985,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-04-21T21:11:43.000Z","date":"2021-04-20","kind":"exercise","acquired":true,"shares":12513,"price":35.16,"value":439957.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":28000,"source":{"system":"sec-edgar","filing":"0001439222-21-000036","document":"wf-form4_161903949035322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000036/wf-form4_161903949035322.xml","form_type":"4"}},{"id":2742984,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-04-21T21:11:43.000Z","date":"2021-04-19","kind":"sale","acquired":false,"shares":3210,"price":55.1572,"value":177054.612,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $55.00 to $55.40. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":15487,"source":{"system":"sec-edgar","filing":"0001439222-21-000036","document":"wf-form4_161903949035322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000036/wf-form4_161903949035322.xml","form_type":"4"}},{"id":2742983,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-04-21T21:11:43.000Z","date":"2021-04-19","kind":"exercise","acquired":true,"shares":3210,"price":35.16,"value":112863.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 77 shares purchased through the Company's employee stock purchase plan."}],"balance_after":18697,"source":{"system":"sec-edgar","filing":"0001439222-21-000036","document":"wf-form4_161903949035322.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000036/wf-form4_161903949035322.xml","form_type":"4"}},{"id":2835709,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2021-02-24T21:11:44.000Z","date":"2021-02-22","kind":"exercise","acquired":false,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":3333,"derivative":{"underlying":"Common stock","underlying_shares":3334},"source":{"system":"sec-edgar","filing":"0001439222-21-000020","document":"wf-form4_161420108188627.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000020/wf-form4_161420108188627.xml","form_type":"4"}},{"id":2835708,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-02-24T21:11:44.000Z","date":"2021-02-24","kind":"tax_withholding","acquired":false,"shares":986,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15410,"source":{"system":"sec-edgar","filing":"0001439222-21-000020","document":"wf-form4_161420108188627.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000020/wf-form4_161420108188627.xml","form_type":"4"}},{"id":2835707,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-02-24T21:11:44.000Z","date":"2021-02-22","kind":"exercise","acquired":true,"shares":3334,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":16396,"source":{"system":"sec-edgar","filing":"0001439222-21-000020","document":"wf-form4_161420108188627.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000020/wf-form4_161420108188627.xml","form_type":"4"}},{"id":2854260,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock unit","published_at":"2021-02-17T21:14:12.000Z","date":"2021-02-16","kind":"exercise","acquired":false,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001439222-21-000012","document":"wf-form4_161359643259356.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000012/wf-form4_161359643259356.xml","form_type":"4"}},{"id":2854259,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2021-02-17T21:14:12.000Z","date":"2021-02-14","kind":"exercise","acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":8000,"derivative":{"underlying":"Common stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001439222-21-000012","document":"wf-form4_161359643259356.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000012/wf-form4_161359643259356.xml","form_type":"4"}},{"id":2854258,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-02-17T21:14:12.000Z","date":"2021-02-16","kind":"tax_withholding","acquired":false,"shares":2069,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":13062,"source":{"system":"sec-edgar","filing":"0001439222-21-000012","document":"wf-form4_161359643259356.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000012/wf-form4_161359643259356.xml","form_type":"4"}},{"id":2854257,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-02-17T21:14:12.000Z","date":"2021-02-16","kind":"exercise","acquired":true,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":15131,"source":{"system":"sec-edgar","filing":"0001439222-21-000012","document":"wf-form4_161359643259356.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000012/wf-form4_161359643259356.xml","form_type":"4"}},{"id":2854256,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2021-02-17T21:14:12.000Z","date":"2021-02-14","kind":"exercise","acquired":true,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 75 shares purchased through the Company's employee stock purchase plan."}],"balance_after":12381,"source":{"system":"sec-edgar","filing":"0001439222-21-000012","document":"wf-form4_161359643259356.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000012/wf-form4_161359643259356.xml","form_type":"4"}},{"id":2863116,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-02-12T21:22:56.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":44000,"derivative":{"exercise_price":56.68,"expiration_date":"2031-02-10","underlying":"Common stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001439222-21-000005","document":"wf-form4_161316494927551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000005/wf-form4_161316494927551.xml","form_type":"4"}},{"id":2863115,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2021-02-12T21:22:56.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":11000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":11000,"derivative":{"underlying":"Common stock","underlying_shares":11000},"source":{"system":"sec-edgar","filing":"0001439222-21-000005","document":"wf-form4_161316494927551.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922221000005/wf-form4_161316494927551.xml","form_type":"4"}},{"id":3136535,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-22T21:09:05.000Z","date":"2020-05-21","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the \"Plan\") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date."}],"balance_after":24000,"derivative":{"exercise_price":0.6261,"expiration_date":"2030-05-20","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-20-031816","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000120919120031816/doc4.xml","form_type":"4"}},{"id":3139045,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-05-21T21:05:42.000Z","date":"2020-05-20","kind":"exercise","acquired":false,"shares":3583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":15723,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":3583},"source":{"system":"sec-edgar","filing":"0001439222-20-000041","document":"wf-form4_159009512439488.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000041/wf-form4_159009512439488.xml","form_type":"4"}},{"id":3139044,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-05-21T21:05:42.000Z","date":"2020-05-20","kind":"sale","acquired":false,"shares":3583,"price":50.014,"value":179200.162,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.05. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":8306,"source":{"system":"sec-edgar","filing":"0001439222-20-000041","document":"wf-form4_159009512439488.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000041/wf-form4_159009512439488.xml","form_type":"4"}},{"id":3139043,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-05-21T21:05:42.000Z","date":"2020-05-20","kind":"exercise","acquired":true,"shares":3583,"price":35.16,"value":125978.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 76 shares purchased through the Company's employee stock purchase plan."}],"balance_after":11889,"source":{"system":"sec-edgar","filing":"0001439222-20-000041","document":"wf-form4_159009512439488.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000041/wf-form4_159009512439488.xml","form_type":"4"}},{"id":3176454,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2020-04-15T20:25:37.000Z","date":"2020-04-13","kind":"exercise","acquired":false,"shares":5280,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service.  The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service.  The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":10561,"derivative":{"underlying":"Common stock","underlying_shares":5280},"source":{"system":"sec-edgar","filing":"0001439222-20-000028","document":"wf-form4_158698231920894.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000028/wf-form4_158698231920894.xml","form_type":"4"}},{"id":3176453,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-04-15T20:25:37.000Z","date":"2020-04-14","kind":"tax_withholding","acquired":false,"shares":2368,"price":40.64,"value":96235.52,"ownership":{"direct":true},"balance_after":8230,"source":{"system":"sec-edgar","filing":"0001439222-20-000028","document":"wf-form4_158698231920894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000028/wf-form4_158698231920894.xml","form_type":"4"}},{"id":3176452,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-04-15T20:25:37.000Z","date":"2020-04-13","kind":"exercise","acquired":true,"shares":5280,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":10598,"source":{"system":"sec-edgar","filing":"0001439222-20-000028","document":"wf-form4_158698231920894.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000028/wf-form4_158698231920894.xml","form_type":"4"}},{"id":3249127,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2020-02-25T21:26:11.000Z","date":"2020-02-22","kind":"exercise","acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":6667,"derivative":{"underlying":"Common stock","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0001439222-20-000023","document":"wf-form4_158266595418246.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000023/wf-form4_158266595418246.xml","form_type":"4"}},{"id":3249126,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-25T21:26:11.000Z","date":"2020-02-24","kind":"tax_withholding","acquired":false,"shares":1596,"price":48.66,"value":77661.36,"ownership":{"direct":true},"balance_after":5318,"source":{"system":"sec-edgar","filing":"0001439222-20-000023","document":"wf-form4_158266595418246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000023/wf-form4_158266595418246.xml","form_type":"4"}},{"id":3249125,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-25T21:26:11.000Z","date":"2020-02-22","kind":"exercise","acquired":true,"shares":3333,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":6914,"source":{"system":"sec-edgar","filing":"0001439222-20-000023","document":"wf-form4_158266595418246.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000023/wf-form4_158266595418246.xml","form_type":"4"}},{"id":3262926,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock unit","published_at":"2020-02-19T21:53:58.000Z","date":"2020-02-16","kind":"exercise","acquired":false,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":2750,"derivative":{"underlying":"Common stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001439222-20-000018","document":"wf-form4_158214922111232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000018/wf-form4_158214922111232.xml","form_type":"4"}},{"id":3262925,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-02-19T21:53:58.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 14, 2020. The shares underlying this option vest as to 25% of the underlying shares on February 14, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":45000,"derivative":{"exercise_price":51.51,"expiration_date":"2030-02-14","underlying":"Common stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001439222-20-000018","document":"wf-form4_158214922111232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000018/wf-form4_158214922111232.xml","form_type":"4"}},{"id":3262924,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2020-02-19T21:53:58.000Z","date":"2020-02-14","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 14, 2020. Beginning on February, 2021, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":12000,"derivative":{"underlying":"Common stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001439222-20-000018","document":"wf-form4_158214922111232.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000018/wf-form4_158214922111232.xml","form_type":"4"}},{"id":3262923,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-19T21:53:58.000Z","date":"2020-02-18","kind":"tax_withholding","acquired":false,"shares":819,"price":52.01,"value":42596.19,"ownership":{"direct":true},"balance_after":3581,"source":{"system":"sec-edgar","filing":"0001439222-20-000018","document":"wf-form4_158214922111232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000018/wf-form4_158214922111232.xml","form_type":"4"}},{"id":3262922,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-19T21:53:58.000Z","date":"2020-02-16","kind":"exercise","acquired":true,"shares":2750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":4400,"source":{"system":"sec-edgar","filing":"0001439222-20-000018","document":"wf-form4_158214922111232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000018/wf-form4_158214922111232.xml","form_type":"4"}},{"id":3266645,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-02-18T21:05:33.000Z","date":"2020-02-13","kind":"exercise","acquired":false,"shares":7100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":19306,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":7100},"source":{"system":"sec-edgar","filing":"0001439222-20-000008","document":"wf-form4_158205991627413.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000008/wf-form4_158205991627413.xml","form_type":"4"}},{"id":3266644,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-18T21:05:33.000Z","date":"2020-02-13","kind":"sale","acquired":false,"shares":7100,"price":50.1566,"value":356111.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.82. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":1650,"source":{"system":"sec-edgar","filing":"0001439222-20-000008","document":"wf-form4_158205991627413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000008/wf-form4_158205991627413.xml","form_type":"4"}},{"id":3266643,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-18T21:05:33.000Z","date":"2020-02-13","kind":"exercise","acquired":true,"shares":7100,"price":35.16,"value":249636.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":8750,"source":{"system":"sec-edgar","filing":"0001439222-20-000008","document":"wf-form4_158205991627413.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000008/wf-form4_158205991627413.xml","form_type":"4"}},{"id":3273817,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-02-13T21:21:23.000Z","date":"2020-02-11","kind":"exercise","acquired":false,"shares":621,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":26406,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":621},"source":{"system":"sec-edgar","filing":"0001439222-20-000006","document":"wf-form4_158162886617100.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000006/wf-form4_158162886617100.xml","form_type":"4"}},{"id":3273816,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-13T21:21:23.000Z","date":"2020-02-11","kind":"sale","acquired":false,"shares":621,"price":50.0213,"value":31063.2273,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.06. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":1650,"source":{"system":"sec-edgar","filing":"0001439222-20-000006","document":"wf-form4_158162886617100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000006/wf-form4_158162886617100.xml","form_type":"4"}},{"id":3273815,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-13T21:21:23.000Z","date":"2020-02-11","kind":"exercise","acquired":true,"shares":621,"price":35.16,"value":21834.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2271,"source":{"system":"sec-edgar","filing":"0001439222-20-000006","document":"wf-form4_158162886617100.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000006/wf-form4_158162886617100.xml","form_type":"4"}},{"id":3286463,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-02-06T21:52:27.000Z","date":"2020-02-05","kind":"exercise","acquired":false,"shares":35447,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":27027,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":35447},"source":{"system":"sec-edgar","filing":"0001439222-20-000005","document":"wf-form4_158102593034853.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000005/wf-form4_158102593034853.xml","form_type":"4"}},{"id":3286462,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-02-06T21:52:27.000Z","date":"2020-02-04","kind":"exercise","acquired":false,"shares":8526,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":62474,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":8526},"source":{"system":"sec-edgar","filing":"0001439222-20-000005","document":"wf-form4_158102593034853.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000005/wf-form4_158102593034853.xml","form_type":"4"}},{"id":3286461,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-06T21:52:27.000Z","date":"2020-02-04","kind":"sale","acquired":false,"shares":35447,"price":50.1037,"value":1776025.8539,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.46. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":1650,"source":{"system":"sec-edgar","filing":"0001439222-20-000005","document":"wf-form4_158102593034853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000005/wf-form4_158102593034853.xml","form_type":"4"}},{"id":3286460,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-06T21:52:27.000Z","date":"2020-02-05","kind":"exercise","acquired":true,"shares":35447,"price":35.16,"value":1246316.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":37097,"source":{"system":"sec-edgar","filing":"0001439222-20-000005","document":"wf-form4_158102593034853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000005/wf-form4_158102593034853.xml","form_type":"4"}},{"id":3286459,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-06T21:52:27.000Z","date":"2020-02-04","kind":"sale","acquired":false,"shares":14191,"price":50.0291,"value":709962.9581,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $50.00 to $50.23. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":1650,"source":{"system":"sec-edgar","filing":"0001439222-20-000005","document":"wf-form4_158102593034853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000005/wf-form4_158102593034853.xml","form_type":"4"}},{"id":3286458,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2020-02-06T21:52:27.000Z","date":"2020-02-04","kind":"exercise","acquired":true,"shares":8526,"price":35.16,"value":299774.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 77 shares purchased through the Company's employee stock purchase plan."}],"balance_after":15841,"source":{"system":"sec-edgar","filing":"0001439222-20-000005","document":"wf-form4_158102593034853.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922220000005/wf-form4_158102593034853.xml","form_type":"4"}},{"id":3323834,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-03T22:02:46.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":50562,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date."}],"balance_after":50562,"derivative":{"exercise_price":4.72,"expiration_date":"2029-12-31","underlying":"Common Stock","underlying_shares":50562},"source":{"system":"sec-edgar","filing":"0001209191-20-001164","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919120001164/doc4.xml","form_type":"4"}},{"id":3386394,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-10-30T01:09:06.000Z","date":"2019-10-25","kind":"grant","acquired":true,"shares":94031,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest on October 8, 2021, subject to Reporting Person's continuous service with the Issuer through such date."}],"balance_after":94031,"derivative":{"exercise_price":4.26,"expiration_date":"2029-10-25","underlying":"Common Stock","underlying_shares":94031},"source":{"system":"sec-edgar","filing":"0001209191-19-054401","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919119054401/doc4.xml","form_type":"4"}},{"id":3480928,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-21T21:12:58.000Z","date":"2019-06-19","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the \"Plan\") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date."}],"balance_after":12000,"derivative":{"exercise_price":2.36,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-19-038556","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1590750/000120919119038556/doc4.xml","form_type":"4"}},{"id":3564520,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-04-03T20:12:33.000Z","date":"2019-04-01","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":71000,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-023072","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/doc4.xml","form_type":"4"}},{"id":3564519,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-04-03T20:12:33.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":100,"price":68.72,"value":6872.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":7238,"source":{"system":"sec-edgar","filing":"0001209191-19-023072","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/doc4.xml","form_type":"4"}},{"id":3564518,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-04-03T20:12:33.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":1500,"price":68.09,"value":102135.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $67.71 to $68.55. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7338,"source":{"system":"sec-edgar","filing":"0001209191-19-023072","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/doc4.xml","form_type":"4"}},{"id":3564517,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-04-03T20:12:33.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":2546,"price":66.85,"value":170200.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $66.50 to $67.07. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":8838,"source":{"system":"sec-edgar","filing":"0001209191-19-023072","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/doc4.xml","form_type":"4"}},{"id":3564516,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-04-03T20:12:33.000Z","date":"2019-04-01","kind":"sale","acquired":false,"shares":5854,"price":66.03,"value":386539.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $65.50 to $66.49. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":11384,"source":{"system":"sec-edgar","filing":"0001209191-19-023072","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/doc4.xml","form_type":"4"}},{"id":3564515,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-04-03T20:12:33.000Z","date":"2019-04-01","kind":"exercise","acquired":true,"shares":10000,"price":35.16,"value":351600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":17238,"source":{"system":"sec-edgar","filing":"0001209191-19-023072","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119023072/doc4.xml","form_type":"4"}},{"id":3586440,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-03-19T20:25:00.000Z","date":"2019-03-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":81000,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-020288","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119020288/doc4.xml","form_type":"4"}},{"id":3586439,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-03-19T20:25:00.000Z","date":"2019-03-15","kind":"sale","acquired":false,"shares":1300,"price":64.64,"value":84032.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $64.59 to $64.68. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":7238,"source":{"system":"sec-edgar","filing":"0001209191-19-020288","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119020288/doc4.xml","form_type":"4"}},{"id":3586438,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-03-19T20:25:00.000Z","date":"2019-03-15","kind":"sale","acquired":false,"shares":8700,"price":64.09,"value":557583.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $63.54 to $64.46. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":8538,"source":{"system":"sec-edgar","filing":"0001209191-19-020288","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119020288/doc4.xml","form_type":"4"}},{"id":3586437,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-03-19T20:25:00.000Z","date":"2019-03-15","kind":"exercise","acquired":true,"shares":10000,"price":35.16,"value":351600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 43 shares purchased through the Company's employee stock purchase plan."}],"balance_after":17238,"source":{"system":"sec-edgar","filing":"0001209191-19-020288","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119020288/doc4.xml","form_type":"4"}},{"id":3631958,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock units","published_at":"2019-02-26T21:25:28.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 22, 2019. Beginning on February 22, 2020, the shares underlying the restricted stock units will vest in three equal annual installments."}],"balance_after":10000,"derivative":{"underlying":"Common stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-013531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119013531/doc4.xml","form_type":"4"}},{"id":3631957,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-02-26T21:25:28.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 22, 2019. The shares underlying this option vest as to 25% of the underlying shares on February 22, 2020, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":40000,"derivative":{"exercise_price":58.86,"expiration_date":"2029-02-22","underlying":"Common stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-19-013531","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119013531/doc4.xml","form_type":"4"}},{"id":3645717,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Restricted stock unit","published_at":"2019-02-20T21:04:07.000Z","date":"2019-02-16","kind":"exercise","acquired":false,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":5500,"derivative":{"underlying":"Common stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001209191-19-011489","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011489/doc4.xml","form_type":"4"}},{"id":3645716,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-02-20T21:04:07.000Z","date":"2019-02-19","kind":"tax_withholding","acquired":false,"shares":818,"price":58.03,"value":47468.54,"ownership":{"direct":true},"balance_after":7195,"source":{"system":"sec-edgar","filing":"0001209191-19-011489","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011489/doc4.xml","form_type":"4"}},{"id":3645715,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-02-20T21:04:07.000Z","date":"2019-02-16","kind":"exercise","acquired":true,"shares":2750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 34 shares purchased through the Company's employee stock purchase plan."}],"balance_after":8013,"source":{"system":"sec-edgar","filing":"0001209191-19-011489","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011489/doc4.xml","form_type":"4"}},{"id":3689308,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share unit","published_at":"2019-01-23T21:12:30.000Z","date":"2019-01-20","kind":"exercise","acquired":false,"shares":6265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":6265},"source":{"system":"sec-edgar","filing":"0001209191-19-004950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119004950/doc4.xml","form_type":"4"}},{"id":3689307,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-01-23T21:12:30.000Z","date":"2019-01-22","kind":"tax_withholding","acquired":false,"shares":1960,"price":52.82,"value":103527.2,"ownership":{"direct":true},"balance_after":5229,"source":{"system":"sec-edgar","filing":"0001209191-19-004950","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119004950/doc4.xml","form_type":"4"}},{"id":3689306,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2019-01-23T21:12:30.000Z","date":"2019-01-20","kind":"exercise","acquired":true,"shares":6265,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":7189,"source":{"system":"sec-edgar","filing":"0001209191-19-004950","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119004950/doc4.xml","form_type":"4"}},{"id":3828661,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-08-31T20:02:36.000Z","date":"2018-08-30","kind":"exercise","acquired":false,"shares":1700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":91000,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":1700},"source":{"system":"sec-edgar","filing":"0001209191-18-049065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118049065/doc4.xml","form_type":"4"}},{"id":3828660,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-08-31T20:02:36.000Z","date":"2018-08-29","kind":"exercise","acquired":false,"shares":300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":92700,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":300},"source":{"system":"sec-edgar","filing":"0001209191-18-049065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118049065/doc4.xml","form_type":"4"}},{"id":3828659,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2018-08-31T20:02:36.000Z","date":"2018-08-30","kind":"sale","acquired":false,"shares":1700,"price":80.03,"value":136051.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is the weighted average of the shares sold.  The shares were sold at varying prices in the range of $80.00 to $80.28. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price."}],"balance_after":924,"source":{"system":"sec-edgar","filing":"0001209191-18-049065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118049065/doc4.xml","form_type":"4"}},{"id":3828658,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2018-08-31T20:02:36.000Z","date":"2018-08-30","kind":"exercise","acquired":true,"shares":1700,"price":35.16,"value":59772.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2624,"source":{"system":"sec-edgar","filing":"0001209191-18-049065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118049065/doc4.xml","form_type":"4"}},{"id":3828657,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2018-08-31T20:02:36.000Z","date":"2018-08-29","kind":"sale","acquired":false,"shares":300,"price":80,"value":24000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":924,"source":{"system":"sec-edgar","filing":"0001209191-18-049065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118049065/doc4.xml","form_type":"4"}},{"id":3828656,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common stock","published_at":"2018-08-31T20:02:36.000Z","date":"2018-08-29","kind":"exercise","acquired":true,"shares":300,"price":35.16,"value":10548.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":1224,"source":{"system":"sec-edgar","filing":"0001209191-18-049065","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118049065/doc4.xml","form_type":"4"}},{"id":3862187,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Performance share units","published_at":"2018-07-24T20:32:16.000Z","date":"2018-07-20","kind":"grant","acquired":true,"shares":6265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The performance share units were originally granted on December 21, 2015. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":6265,"derivative":{"underlying":"Common Stock","underlying_shares":6265},"source":{"system":"sec-edgar","filing":"0001209191-18-043729","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118043729/doc4.xml","form_type":"4"}},{"id":3868643,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":39731,"kind":"person","name":"Bowden Christopher","position":1,"cik":"0001608601","reported_name":"Bowden Christopher","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-07-12T20:14:48.000Z","date":"2018-07-10","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on May 31, 2014. The shares underlying this option vest as to 25% of the underlying shares on May 13, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":93000,"derivative":{"exercise_price":35.16,"expiration_date":"2024-05-30","underlying":"Common stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-18-042453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118042453/doc4.xml","form_type":"4"}}],"next_cursor":"2018-07-12T20:14:48.000000Z,3868643"}